From the publishers of JADPRO
Multiple Myeloma
Resource Center
Menu
Resources
Videos
Videos
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge in a first relapse case
Last Updated: Thursday, November 16, 2023
First Relapse of Multiple Myeloma Patient
Loading...
Advertisement
News & Literature Highlights
Blood and Lymphatic Cancer: Targets and Therapy
The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review
Leukemia & Lymphoma
Are we maintaining minimal residual disease in myeloma?
Clinical Cancer Research
Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory multiple myeloma
Presse Medicale
Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma
Journal of Patient-Reported Outcomes
Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma
Blood Advances
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Cancer Metastasis Reviews
CAR T-cell therapy to treat multiple myeloma: Current state and future directions
Journal of Cancer Policy
Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?
Cancer Medicine
Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma
Pharmaceuticals
Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study
Advertisement
Case Studies
Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy
Single Solitary Plasmacytoma to Active Myeloma
A Heavily Treated Relapsed/Refractory Multiple Myeloma Patient on Talquetamab
Advertisement
Quizzes
Test your knowledge on managing a patient newly diagnosed with MM and ineligible for stem-cell transplant
Test your knowledge of newly diagnosed multiple myeloma
Test your knowledge in a first relapse case